MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Bristol-Myers Squibb Co.

Gesloten

SectorGezondheidszorg

57.76 -3.05

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

57.75

Max

60.69

Belangrijke statistieken

By Trading Economics

Inkomsten

-1.1B

76M

Verkoop

442M

12B

K/W

Sectorgemiddelde

14.05

63.778

EPS

1.67

Dividendrendement

4.07

Winstmarge

0.616

Werknemers

34,100

EBITDA

-1.9B

2.6B

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+2.23% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

4.07%

2.39%

Volgende Winsten

24 apr 2025

Volgende dividenddatum

1 mei 2025

Volgende Ex Dividend datum

4 apr 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

311M

121B

Vorige openingsprijs

60.81

Vorige sluitingsprijs

57.76

Nieuwssentiment

By Acuity

37%

63%

130 / 386 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

Bristol-Myers Squibb Co. Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 mrt 2025, 10:13 UTC

Belangrijke Marktbewegers
Acquisities, Fusies, Overnames

2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers

11 mrt 2025, 10:13 UTC

Belangrijke Marktbewegers
Acquisities, Fusies, Overnames

2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers

6 feb 2025, 12:13 UTC

Winsten

Bristol Myers Squibb's 4Q Beats Forecasts; Generics Dent 2025 Outlook

14 mrt 2025, 09:30 UTC

Top Nieuws

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

11 mrt 2025, 02:26 UTC

Acquisities, Fusies, Overnames

Abecma Is an Immunotherapy Indicated for Treatment of Relapsed or Refractory Multiple Myeloma >TSVT

11 mrt 2025, 02:26 UTC

Acquisities, Fusies, Overnames

Stockholders Owning About 5.3% of 2seventy Bio Shares Have Agreed to Tender All Their Shares >TSVT

11 mrt 2025, 02:26 UTC

Acquisities, Fusies, Overnames

2seventy Bio CEO: Rationale for Deal Clear, in Line With Focus on Unlocking Value of Abecma >TSVT

11 mrt 2025, 02:23 UTC

Acquisities, Fusies, Overnames

2seventy Bio Stock Will No Longer Trade on Nasdaq After Closing of Deal, Expected in 2Q >TSVT

11 mrt 2025, 02:22 UTC

Acquisities, Fusies, Overnames

2seventy Bio's Board Unanimously Recommends Stockholders Tender Shares in Offer >TSVT

11 mrt 2025, 02:21 UTC

Acquisities, Fusies, Overnames

Bristol Myers Deal Represents 88% Premium to 2seventy Closing Price of $2.66 on March 7 >TSVT

11 mrt 2025, 02:21 UTC

Acquisities, Fusies, Overnames

Bristol Myers to Acquire 2seventy Bio Shares at $5.00 Each in All-Cash Deal for Equity Value of About $286M >TSVT

11 mrt 2025, 02:19 UTC

Acquisities, Fusies, Overnames

2seventy Bio Enters Into Definitive Agreement to Be Acquired by Bristol Myers Squibb

28 feb 2025, 12:00 UTC

Top Nieuws

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

6 feb 2025, 15:35 UTC

Winsten

Bristol Myers Wallops Fourth-Quarter Views, But Shares Slide On 2025 Outlook -- IBD

6 feb 2025, 13:56 UTC

Winsten

Bristol Myers Wallops Fourth-Quarter Earnings Views. But Shares Plummet 5%. -- IBD

6 feb 2025, 13:25 UTC

Top Nieuws
Winsten

Bristol Myers Earnings Are a 'Tale of 2 Trends' as Guidance Falls Short. The Stock Is Falling -- Barrons.com

6 feb 2025, 12:00 UTC

Winsten

Bristol Myers Earnings Are 'a Tale of 2 Trends' as Guidance Falls Short -- Barrons.com

6 feb 2025, 11:59 UTC

Winsten

Bristol-Myers Squibb 4Q Gross Margin 61.0% >BMY

6 feb 2025, 11:59 UTC

Winsten

Bristol-Myers Squibb 4Q Rev $12.3B >BMY

6 feb 2025, 11:59 UTC

Winsten

Bristol-Myers Squibb 4Q Net $72M >BMY

6 feb 2025, 11:59 UTC

Winsten

Bristol-Myers Squibb 4Q EPS 4c >BMY

6 feb 2025, 11:59 UTC

Winsten

Bristol-Myers Squibb 4Q Adj EPS $1.67 >BMY

6 feb 2025, 11:59 UTC

Winsten

Bristol Myers Squibb: Expanding Existing Strategic Productivity Initiative to Include About $2B in Additional Annualized Cost Savings by the End of 2027 >BMY

6 feb 2025, 11:59 UTC

Winsten

Bristol Myers Squibb 4Q International Revenue Rose 5% to $3.7B >BMY

6 feb 2025, 11:59 UTC

Winsten

Bristol Myers Squibb 4Q U.S. Revenue Rose 9% to $8.6B >BMY

6 feb 2025, 11:59 UTC

Winsten

Bristol Myers Squibb 4Q Legacy Portfolio Revenue $5.98B, Down 4% >BMY

6 feb 2025, 11:59 UTC

Winsten

Bristol Myers Squibb: 4Q Growth Portfolio Revenue Primarily Due to Higher Demand for Reblozyl, Breyanzi, Camzyos, Yervoy and Opdualag >BMY

6 feb 2025, 11:59 UTC

Winsten

Bristol Myers Squibb 4Q Rev $12.34B >BMY

6 feb 2025, 11:59 UTC

Winsten

Bristol Myers Squibb: 4Q Legacy Portfolio Revenue Lower Vs Yr-Ago Primarily Due to Impact of Generics on Sprycel, Revlimid, Abraxane and Pomalyst, Partially Offset by Higher Demand for Eliquis >BMY

6 feb 2025, 11:59 UTC

Winsten

Bristol Myers Squibb: 2025 Rev Outlook Reflects Near-Term Impact of Generics Across Revlimid, Pomalyst, Sprycel and Abraxane >BMY

Peer Vergelijking

Prijswijziging

Bristol-Myers Squibb Co. Prognose

Koersdoel

By TipRanks

2.23% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 60.93 USD  2.23%

Hoogste 70 USD

Laagste 37 USD

Gebaseerd op 16 Wall Street-analisten die 12-maands prijsdoelen bieden voor Bristol-Myers Squibb Co. - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

16 ratings

5

Buy

10

Hold

1

Sell

Technische score

By Trading Central

59.46 / 61.05Steun & Weerstand

Korte Termijn

Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

130 / 386 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.